Context Therapeutics Reports Second Quarter 2023 Operating

Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,American ,Jennifer Minai Azary ,Martin Lehr ,Gina Cestari ,Hc Wainwright Co ,Nasdaq ,Exchange Commission ,American Society Of Clinical Oncology Annual Meeting ,Twitter ,Linkedin ,Context Therapeutics Inc ,Company Nasdaq ,Investigational New Drug Application ,Recent Corporate ,Biotechnology Conference ,Immune Cell Engager Virtual Conference ,Clinical Oncology Annual Meeting ,Private Securities Litigation Reform Act ,Months Ended June ,Relations Contact ,Nasdaq Cntx ,Ontext Therapeutics Inc ,